SubscribeAll Posts Tagged With: "biotech shorts"
This Bet Pays Off More Than 80% of the Time
You would have made 78% in one day…
Last month, a small biotech company – Synta Pharmaceuticals – suffered a huge drop in its share price. The company announced its lead drug, which treats skin cancer, failed in a pivotal Phase III trial. The stock dropped 78%…
Short sellers profit when stocks crash. And investors who "shorted" Synta’s – who bet against the drug’s approval – walked away with a big paycheck. But shareholders who stuck by Synta were probably shocked…
Synta’s management had done everything right. It ran a "placebo controlled" Phase II trial (that’s the middle hurdle) before it went to…
13Mar2009 | Stansberry and Associates | 0 comments | Continued
Loading ...
